GlaxoSmithKline (GSK) in July spun off its consumer healthcare products division as a separate entity as it transitions into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company aims to prevent and treat disease with innovative vaccines, specialty pharmaceuticals and general medicines.
GSK’s corporate headquarters invests NT$192 billion (US$6.07 billion) annually in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology.
Investing in clinical trial research every year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research centers in Taiwan to help domestic medical research keep pace with international trends and enhance Taiwan’s status as a clinical research center in the Asia-Pacific region.
Photo courtesy of GSK Taiwan
GSK has launched a revamped brand identity system, which has been modified from its old orange logo consisting of a lowercase “gsk” and a beating heart. The new logo adopts a gradient orange, a capital “GSK” and digital and technological lines. Its design brings out a striking and eye-catching image, while conveying GSK’s goals and ideas for the future.
The arrow in the new logo symbolizes the combination of GSK’s digital, social and environmental concerns as a “signal to move forward together” in the biopharmaceutical industry. The curve in the logo symbolizes the ability of the immune system to adapt and evolve with the environment.
GSK’s Taiwan branch was established 43 years ago and has been protecting the health of Taiwanese ever since.
“Having transformed the organization, our new ambitions and our new goal are to expand our impact here in Taiwan by protecting and treating more patients, to make GSK a place where people can thrive, where they can succeed, grow and be happy at work, all supported by doing everything with integrity and care,” said GSK Taiwan Vice President and General Manager Mick Stanley.
The newly transformed GSK focuses on protecting the health of Taiwanese with pharmaceuticals and vaccines, upholding and practicing the values of diversity and inclusion, and caring for employees and practicing sustainability, which form the corporate philosophy of the company.
Being “ambitious for patients” is part of the corporate culture to which GSK attaches great importance.
“In addition to ‘ambitious for patients’, GSK’s culture also emphasizes ‘responsible for impact’. We hope to extend our impacts to Taiwanese,” Stanley said. “We hope we can move forward together to defeat the disease with drugs and vaccines.”
GSK provides up to 50 types of prescription drugs and more than 15 types of vaccines, for children and adults, and strives to do everything possible for the health of Taiwanese people.
Every day, 2 million doses of vaccines produced by GSK are administered worldwide. Over the past few years, GSK has advocated for adult vaccination. For example, GSK Taiwan recently launched a new herpes zoster virus vaccine to protect against shingles.
To help Taiwanese become aware of the need for adult vaccination, GSK is working with entities in Taiwan to create and promote comprehensive information and an environment for adult vaccination.
GSK provides vaccines against infectious diseases that can occur at all stages of life. It helps provide adequate immune protection against meningitis, quadrivalent influenza, poliomyelitis, measles and other diseases. In Taiwan, an average of 40% of children receive vaccines supplied by GSK.
GSK is also concerned about the health issues facing Taiwan’s aging population. Accordingly, GSK has discussed important policy developments with the government through the American Chamber of Commerce in Taiwan, the European Chamber of Commerce in Taiwan and the International Association of Research-Based Pharmaceutical Manufacturers. , with the aim of helping Taiwan establish a solid foundation for its medical development. environment in the decades to come.
Additionally, since the invention of the very first drug for the treatment of HIV, GSK has worked continuously to improve the health and quality of life of people living with HIV, and has cooperated with government entities and patient groups. .
In addition to vaccines, GSK is also the industry leader in the treatment and prevention of diseases such as respiratory diseases. For people with asthma, chronic obstructive pulmonary disease and other respiratory conditions that need medication for treatment, GSK helps them with a variety of inhaled medications.
The world’s first inhaler was developed by GSK.
The company helps more than 2 million people with respiratory diseases every year in Taiwan and enables them to breathe freely with a better quality of life.
Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. The final decision will be at the discretion of The Taipei Times.